PRIMARY OBJECTIVE There has been increasing interest in the role of cholinomimetic agents in the long-term management of cognitive impairment following traumatic brain injury. This paper aims to assess the evidence accumulated thus far. METHODS Studies are identified by searching MEDLINE, EMBASE and PsychINFO, contacting experts and pharmaceutical companies and hand searching bibliographies. ...

Cholinesterase inhibitors such as donepezil, galantamine and rivastigmine can slow the progression of Alzheimer’s disease and provide symptomatic relief but require daily administration (donepezil) or twice daily administration (galantamine and rivastigmine). These medications, of course, only have efficacy if actually taken on a regular basis. A clinical vignette is described here of a patient...

#### Notable in Neurology This Week This issue features an article that examines the link between lateropulsion and spatial neglect patients with acute stroke; another investigates association cholinesterase inhibitors cognitive decline Alzheimer dementia. A featured Views & Reviews incidence prevalence of drug-resistant epilepsy. ### Association White Matter Hyperintensity Markers on MRI Lon...

2-Isopropyl-4-dimethylamino-5-methylphenyl-1-piperidine carboxylate methyl chloride (AMO-1618) inhibits the activity of a cholinesterase isolated from mung bean (Phaseolus aureus) roots at concentrations comparable to those which retard growth and inhibit development of secondary roots of bean seedlings. Fifty per cent inhibition of the cholinesterase activity occurred at 0.21 mm. Inhibition of...

patients examined in this study were taking cholinesterase inhibitors and 22% took memantine. Without strong empirical data, clinical judgmentmust rule.DavidKnopman,MD, a professor of neurology at theMayoClinic in Rochester, Minnesota, usually opts to continue cholinesterase inhibitors for patients withdementiawho liveathomebecausehe doesn’t want to run the risk of precipitating decline.But if ...

The prevalence of dementia is approximately 1.7 - 4.3% among aged people in Taiwan, and Alzheimer disease (AD) is the most common cause of dementia. Although three cholinesterase inhibitors and one glutamate NMDA receptor antagonist are available in Taiwan to treat dementia, their insurance reimbursement is strictly regulated and only a small proportion of patients with AD receive medical treat...

Symptomatic treatment of myasthenia gravis is based on the use of peripherally-acting acetylcholinesterase (AChE) inhibitors that, in some cases, must be discontinued due to the occurrence of a number of side-effects. Thus, new AChE inhibitors are being developed and investigated for their potential use against this disease. Here, we have explored two alternative approaches to get access to per...